For the first time, a complete X-ray diffraction data set has been collected from a myotoxic Asp49-phospholipase A 2 (Asp49-PLA 2 ) with low catalytic activity (BthTX-II from Bothrops jararacussu venom) and a molecular-replacement solution has been obtained with a dimer in the asymmetric unit. The quaternary structure of BthTX-II resembles the myotoxin Asp49-PLA 2 PrTX-III (piratoxin III from B. pirajai venom) and all non-catalytic and myotoxic dimeric Lys49-PLA 2 s. In contrast, the oligomeric structure of BthTX-II is different from the highly catalytic and non-myotoxic BthA-I (acidic PLA 2 from B. jararacussu). Thus, comparison between these structures should add insight into the catalytic and myotoxic activities of bothropic PLA 2 s.
Introduction
Phospholipases A 2 (PLA 2 s; EC 3.1.1.4) belong to a superfamily of proteins which hydrolyze the sn-2 acyl groups of membrane phospholipids to release fatty acids, arachidonic acid and lysophospholipids (van Deenen & de Haas, 1963) . The coordination of the Ca 2+ ion in the PLA 2 calcium-binding loop includes an Asp at position 49 which plays a crucial role in the stabilization of the tetrahedral transition-state intermediate in catalytically active PLA 2 s (Scott et al., 1992) . In the genus Bothrops, PLA 2 s are the main components of the venoms produced by species classified into this animal group. In addition to their primary catalytic role, snake-venom PLA 2 s show other important toxic/pharmacological effects, including myonecrosis, neurotoxicity, cardiotoxicity and haemolytic, haemorrhagic, hypotensive, anticoagulant, platelet-aggregation inhibition and oedemainducing activities (Gutié rrez & Lomonte, 1997; Ownby, 1998; Andriã o-Escarso et al., 2002) . Some of these activities are correlated with the enzymatic activity, but others are completely independent (Kini & Evans, 1989; . It has been suggested that some specific sites of these molecules have biochemical properties that are responsible for the pharmacological and toxic actions, including the anticoagulant and platelet-inhibition activities (Kini & Evans, 1989) . PLA 2 s are also one of the enzymes involved in the production of eicosanoids. These molecules have physiological effects at very low concentrations; however, increases in their concentration can lead to inflammation (Needleman et al., 1986) . Thus, the study of specific PLA 2 inhibitors is important in the production of structurebased anti-inflammatory agents.
Many non-catalytic homologous PLA 2 s (Lys49-PLA 2 s) have been purified from Bothrops snake venoms and have been structurally and functionally characterized (Marchi-Salvador et al., 2005 , 2006 Watanabe et al., 2005; Magro et al., 2003; Lee et al., 2001; Arni et al., 1995 Arni et al., , 1999 da Silva-Giotto et al., 1998) . However, little is known about the bothropic catalytic PLA 2 s (Asp49-PLA 2 s; Magro et al., 2004 Magro et al., , 2005 Rigden et al., 2003; Serrano et al., 1999; Pereira et al., 1998; Daniele et al., 1995; Homsi-Brandeburgo et al., 1988) .
Despite the structures of a large number of PLA 2 s having been solved by crystallography to date, many questions still need to be clarified. For example, there are PLA 2 s with high, moderate and no catalytic activity (Magro et al., 2004; Rigden et al., 2003; da Silva-Giotto et al., 1998) . However, for all these 'classes' of PLA 2 s the majority of residues of the catalytic machinery are conserved. Similarly, toxic (e.g. myotoxity, cytotoxity) and pharmacological effects (e.g. anticoagulant, hypotensive and platelet-aggregation activities) are far from being completely understood.
An acidic catalytic PLA 2 (BthA-I) has been isolated from B. jararacussu venom and characterized (Andriã o-Escarso et al., 2002; Roberto et al., 2004) . BthA-I is three to four times more catalytically active than BthTX-II (bothropstoxin-II from B. jararacussu) and other basic Asp49-PLA 2 s from Bothrops venoms, but is not myotoxic, cytotoxic or lethal (Andriã o-Escarso et al., 2002) . Other activities demonstrated by this enzyme are time-independent oedema induction, hypotensive response in rats and platelet-aggregation inhibition (Andriã o-Escarso et al., 2002) . The crystal structure of BthA-I has been recently described in two conformational states: monomeric and dimeric (Magro et al., 2004) . Additionally, Magro et al. (2005) solved the structure of BthA-I chemically modified with BPB (p-bromophenacyl bromide) and showed important tertiary and quaternary structural changes in this enzyme. This novel oligomeric structure is more energetically and conformationally stable than the native structure and the abolition of pharmacological activities (including anticoagulant, hypotensive effect and platelet-aggregation inhibition) by the ligand may be related to the oligomeric structural changes.
The isolation, biochemical/pharmacological characterization and amino-acid sequence of bothropstoxin II from B. jararacussu (BthTX-II) have been reported (Homsi-Brandeburgo et al., 1988; Gutié rrez et al., 1991; Pereira et al., 1998) . Protein sequencing indicated that BthTX-II is an Asp49-PLA 2 and consists of 120 amino acids (MW = 13 976 Da). The protein shows myotoxic, oedematogenic and haemolytic effects and low phospholipase activity (Homsi-Brandeburgo et al., 1988; Gutié rrez et al., 1991) . Recently, it has been shown that BthTX-II induces platelet aggregation and secretion through multiple signal transduction pathways (Fuly et al., 2004) . Despite BthTX-II having been crystallized more than ten years ago (Bortoleto et al., 1996) , the structure has not been solved to date, probably owing to the low completeness of the data set (50-60% completeness). The crystals belonged to the tetragonal crystal system and preliminary analysis indicated the presence of three molecules in the asymmetric unit (Bortoleto et al., 1996) . However, a careful analysis of the Matthews coefficient indicated that a tetrameric conformation is also possible (V M = 2.4 Å 3 Da À1 ), which also occurs in the Lys49-PLA 2 M j TX-I (myotoxin I from B. moojeni venom) structure formed of two Lys49-PLA 2 dimers (Marchi-Salvador et al.,
2005; personal communication).
In the present paper, we describe the crystallization of BthTX-II (bothropstoxin-II) from B. jararacussu venom in the monoclinic system, the collection of a complete X-ray diffraction data set and molecular-replacement solution. This study should improve the understanding of the relation of the myotoxic and low catalytic activity mechanisms to the structural features of this protein when compared with BthTX-I (Lys49-PLA 2 from B. jararacussu venom) and BthA-I, which possess no and high catalytic activity, respectively.
Experimental procedures 2.1. Purification
BthTX-II was isolated from B. jararacussu snake venom by gelfiltration and ion-exchange chromatography as previously described (Homsi-Brandeburgo et al., 1988) .
Crystallization
A lyophilized sample of BthTX-II was dissolved in ultrapure water at a concentration of 12 mg ml À1 . The sparse-matrix method (Jancarik & Kim, 1991) was used to perform initial screening of the crystallization conditions (Crystal Screens I and II; Hampton Research) . Large crystals of BthTX-II were obtained by the conventional hanging-drop vapour-diffusion method (MacPherson, 1982) , in which 1 ml protein solution and 1 ml reservoir solution were mixed and equilibrated against 500 ml of the same precipitant solution. The BthTX-II was crystallized using a solution containing 20%(v/v) 2-propanol, 13%(w/v) polyethylene glycol 4000 and 0.1 M sodium citrate pH 5.6. The best crystals measured approximately 0.4 Â 0.2 Â 0.1 mm after two months at 291 K (Fig. 1) .
X-ray data collection and processing
X-ray diffraction data from BthTX-II crystals were collected using a wavelength of 1.427 Å at a synchrotron-radiation source (Laborató rio Nacional de Luz Síncrotron, LNLS, Campinas, Brazil) with a MAR CCD imaging-plate detector (MAR Research). A crystal was mounted in a nylon loop and flash-cooled in a stream of nitrogen at 100 K using no cryoprotectant. The crystal-to-detector distance was 100 mm and an oscillation range of 1 was used; 149 images were collected. The data were processed to 2.13 Å resolution using the HKL program package (Otwinowski & Minor, 1997) .
Results and discussion
The data-collection statistics are shown in Table 1 . The data set is 96.1% complete at 2.13 Å resolution, with R merge = 9.1%. The crystals belong to space group C2, with unit-cell parameters a = 58.9, b = 98.5, c = 46.7 Å , = 125.9 .
Packing parameter calculations based on the protein molecular weight indicate the presence of a dimer in the asymmetric unit. This corresponds to a Matthews coefficient (Matthews, 1968 ) of 2.0 Å 3 Da À1 with a calculated solvent content of 37.4%, which are within the expected range for typical protein crystals (assuming a value of 0.74 cm 3 g À1 for the protein partial specific volume).
The crystal structure was determined by molecular-replacement techniques implemented in the program AMoRe (Navaza, 1994) using the coordinates of a monomer of PrTX-III (PDB code 1gmz). The quaternary structure of BthTX-II is very similar to those of PrTX-III and all dimeric bothropic Lys49-PLA 2 s (Rigden et al., 2003; (Magro et al., 2004 (Magro et al., , 2005 Takeda et al., 2004) .
In conclusion, a complete X-ray diffraction data set has been collected from a low catalytic activity Asp49-PLA 2 for the first time (to 2.13 Å ) and a molecular-replacement structure solution has been obtained. The quaternary structure of BthTX-II resembles those of the myotoxin PrTX-III (which does not bind Ca 2+ ions) and all noncatalytic and myotoxic dimeric Lys49-PLA 2 s (Rigden et al., 2003; . In contrast, the oligomeric structure of BthTX-II is different from that of the high catalytic activity and non-myotoxic BthA-I (Magro et al., 2004) . Thus, comparison between these structures should add insight into the catalytic and myotoxic activities of bothropic PLA 2 s. Synchrotron (LNLS-MX1) Data-collection temperature (K) 100 (I) cutoff for data processing ‡ À3 Average I/(I) 10.6 (3.7) Redundancy 3.0 (2.9) Matthews coefficient V M (Å 3 Da À1 ) 2 . 0 Molecules in the ASU 2 Solvent content (%) 37.4 † R merge = P hkl ½ P i ðjI hkl;i À hI hkl ijÞ= P hkl;i hI hkl i, where I hkl,i is the intensity of an individual measurement of the reflection with Miller indices hkl and hI hkl i is the mean intensity of that reflection. Calculated for I > À3(I). ‡ Data processing used the HKL suite (Otwinowski & Minor, 1997) .
